Noteworthy, in a patient with ATC resulted BRAFV600E and PD-L1 positive by NGS and IHC, sequential treatment with BRAF inhibitor vemurafenib and nivolumab led to a substantial regression of the tumor, with a complete radiographic and clinical remission 20 months after the beginning of the treatment (111). This evidence concerns the gene CD274 and neoplasm.